The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
Open accessThe DOI matches its Crossref record; 246 of the 246 references it cites were found in a registry or an index.
Abstract
Human fungal pathogens are attributable to a significant economic burden and mortality worldwide. Antifungal treatments, although limited in number, play a pivotal role in decreasing mortality and morbidities posed by invasive fungal infections (IFIs). However, the recent emergence of multidrug-resistant Candida auris and Candida glabrata and acquiring invasive infections due to azole-resistant C. parapsilosis, C. tropicalis, and Aspergillus spp. in azole-naïve patients pose a serious health threat considering the limited number of systemic antifungals available to treat IFIs. Although advancing for major fungal pathogens, the understanding of fungal attributes contributing to antifungal resistance is just emerging for several clinically important MDR fungal pathogens. Further complicating the matter are the distinct differences in antifungal resistance mechanisms among various fungal species in which one or more mechanisms may contribute to the resistance phenotype. In this review, we attempt to summarize the burden of antifungal resistance for selected non-albicansCandida and clinically important Aspergillus species together with their phylogenetic placement on the tree of life. Moreover, we highlight the different molecular mechanisms between antifungal tolerance and resistance, and comprehensively discuss the molecular mechanisms of antifungal resistance in a species level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Phylogenetic tree of Candida species studied in the current review, i.e., C. glabrata, C. parapsilosis, C. tropicalis, and C. auris (highlighted in blue). This tree was constructed using maximum likelihood of 11,570 core genes based on 1000 replicates. Asterikes does not serve any specific defnitions. This figure was adopted permission from Munoz et al., 2018 [20].](https://figures.cochat.ai/paper-figures/3e30acfc216a4d828861bcc55bf652a6/the-quiet-and-underappreciated-rise-of-drug-resistant-invasive-fungal-pathogens-figure-1.jpg)

![Figure 3 Pdr1p contains four domains. Numerous GOF mutations (black bars) can cause azole resistance. Adopted the permission from Ferrari et al., 2009 [98].](https://figures.cochat.ai/paper-figures/bd4edb3b814e44a689549f07abf351f4/the-quiet-and-underappreciated-rise-of-drug-resistant-invasive-fungal-pathogens-figure-3.jpg)

![Figure 5 Whole-genome sequence analysis of the US C. auris (up to 2018) isolates reveals the existence of four major clades. Isolates representing all identified clades have been recovered from the U.S. The Iranian clade is not shown in this figure. Adopted the permission from Chow et al., 2018 [201].](https://figures.cochat.ai/paper-figures/6559288ef9344e4d9a16d7f660126cfa/the-quiet-and-underappreciated-rise-of-drug-resistant-invasive-fungal-pathogens-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In the US, fluconazole resistance rates range between 4–10%; rates are much higher in other parts of the world including Japan, Western Europe, and Latin America.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [112]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“C. krusei is considered inherently resistant to fluconazole yet demonstrates variable susceptibility to both voriconazole and posaconazole.62,103,112”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fluconazole resistance has been reported in up to 75% of C. glabrata isolates in single center surveys, and resistance to the echinocandins ranges from 0% to 24% in larger studies.27,111–113”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resistance to the echinocandins has remained relatively infrequent (0–3%) despite a higher baseline susceptible MIC cutoff value compared to the other Candida spp. due to a naturally occurring polymorphism in FKS1.62,103,112,120”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resistance to the echinocandins has remained relatively infrequent (0–3%) despite a higher baseline susceptible MIC cutoff value compared to the other Candida spp. due to a naturally occurring polymorphism in FKS1.62,103,112,120”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [112]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662
Satoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298
Phylogeny, identification and nomenclature of the genus Aspergillus
Samson, R. A., Visagie, C. M., Houbraken, J., Hong, S.-B., Hubka, V., Klaassen, C. H. W., Perrone, G., Seifert, K. A., Susca, A., Tanney, J. B., et al. (2014) · Studies in Mycology · doi:10.1016/j.simyco.2014.07.004 · Cited by 1,136
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Self-citationPfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · cited 1×
“At the institutional level, the prevalence of echinocandin resistance can vary significantly, reaching up to >13% at some centers [96].”
BackgroundSelf-citation
Cited by
Items 101–145 of 145
Ira-Bonouman, A., Krasteva, D., Kouadjo, F. K., Roger, F., Bellet, V., Koffi, D., Pottier, C., Touré, O. A., Drakulovski, P., Djaman, A. J., et al. (2023) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2023.101410 · Cited by 7
Azeem, K., Irfan, I., Shakir, M., Rawat, D. S., & Abid, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-5165-5_19 · Cited by 6
Current Updates on Pathogenesis, Systemic Therapy, and Treatment of Invasive Fungal Infections
Singh, S. K., & Pancholi, S. S. (2024) · Current Drug Targets · doi:10.2174/0113894501337502241015121015 · Cited by 5
Benzo[a]phenoxazine derivative C34 efficacy against fluconazole-resistant Candida spp.
Pacheco, M. I., Carvalho-Pereira, J., Costa‐Barbosa, A., Marques, F., Durães, P. M., Gonçalves, M. S. T., Sousa, M. J., & Sampaio, P. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107498 · Cited by 4
Zaragoza, Ó., Alcázar‐Fuoli, L., Trevijano‐Contador, N., Torres-Cano, A., Carballo-González, C., Puig‐Asensio, M., Martín-Gómez, M. T., Jiménez‐Martínez, E., Herrero, D. R., Nuvials, X., et al. (2022) · medRxiv · doi:10.1101/2022.06.06.22275514 · Cited by 4
Luca, D. G. D., Alexander, D. C., Dingle, T. C., Dufresne, P. J., Fuller, J., German, G. J., Haldane, D. J. M., Hoang, L., Jiao, L., Kus, J. V., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.01803-25 · Cited by 3
“C. glabrata has become a recognized nosocomial pathogen with increasing incidence of invasive disease (3), which is of particular concern since fungal infections by this species are amongst those most often associated with antifungal resistance (6, 7).”
Specifically Targeting Metacaspases of Candida: A New Therapeutic Opportunity
Bienvenu, A., Ballut, L., & Picot, S. (2024) · Journal of Fungi · doi:10.3390/jof10020090 · Cited by 4
Pierantoni, D. C., Giuliano, S., Conti, A., Corte, L., Angelini, J., Cardinali, G., & Tascini, C. (2024) · Journal of Fungi · doi:10.3390/jof10070460 · Cited by 4
Turan, D. (2023) · Haydarpaşa Numune medical journal (Online) · doi:10.14744/hnhj.2023.24572 · Cited by 4
“Therefore, it was concluded that, as in the distribution of species, antifungal-resistant strains might differ according to geographical regions[20,21].”
Pacheco, M. I., Guimarães, B. O., Pereira‐Silva, P., Costa‐Barbosa, A., Gonçalves, M. S. T., Sousa, M. J., & Sampaio, P. (2024) · Molecules · doi:10.3390/molecules29215197 · Cited by 2
Cao, X.-Z., Wang, C.-F., Guo, J.-Z., Wen, Y.-H., Wang, W.-H., Wei, M., & Shao, C. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118891 · Cited by 3
Isolation of antifungal-resistant yeasts from bulk milk in Japan
MIYAKE, R., Takakaki, I. T. O., Kamata, H., & Kano, R. (2021) · Journal of Veterinary Medical Science · doi:10.1292/jvms.21-0023 · Cited by 2
“kudriavzevii are intrinsically resistant or less susceptible to antifungals [1, 2], and they have also been isolated from bovine clinical mastitis cases in Japan [5].”
BackgroundInfluentialGreen Fungus Challenges in Post-COVID Health Landscape
Jeha, J., Sudha, S., B, G. N., & Benitta Sherine, S. (2024) · Journal of Angiotherapy · doi:10.25163/angiotherapy.829463 · Cited by 2
Molecular Epidemiology and Antifungal Susceptibility Profile of Candidozyma Isolates From Argentina
Taverna, C. G., Córdoba, S. B., Haim, M. S., Lombardo, M., Vivot, M. E., Arias, B. A., Vivot, W., Szusz, W., Abbey, D., Poklépovich, T., et al. (2025) · Mycoses · doi:10.1111/myc.70025 · Cited by 2
“However, MIC determination is time-consuming and interpretation may vary between protocols [36].”
Baugh, S. P. D., Chaly, A. L., Weaver, D. G., Whitman, D. B., Pelletier, J. C., Bian, H., Freeman, K. B., Reitz, A. B., & Scott, R. W. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03083-1 · Cited by 2
“namely ergosterol (polyenes and azoles) or β-(1,3,)-D-glucan (echinocandins), respectively [12].”
BackgroundHagras, M., Ezzat, H. G., Abuelkhir, A. A., & Mayhoub, A. S. (2025) · RSC Advances · doi:10.1039/d5ra00499c · Cited by 1
Drug resistance in pathogenic species of Candida
Jaiswal, N., & Kumar, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91643-1.00014-4 · Cited by 3
Öztürk, S., Çam, K., Babuççu, G., Onem, U. A., Aydın, S., Kuşkucu, M. A., & Doğan, Ö. (2024) · Microbial Drug Resistance · doi:10.1089/mdr.2023.0198 · Cited by 4
Sharma, S. M., Sharma, R., & Chandrateya, P. (2024) · Infectious Disorders - Drug Targets · doi:10.2174/0118715265317733241021190116 · Cited by 2
Nanotherapeutics and nanotheranostics in miscellaneous fungal infections
Kaur, A., Raj, K., Rajput, P., & Bhatia, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28836-4.00020-2 · Cited by 1
Babu, A. S., & Rao, K. V. B. (2025) · Folia Microbiologica · doi:10.1007/s12223-025-01366-1 · Cited by 1
Hope in the Treatment of Candida Vaginitis: Ibrexafungerp
Karakoyun, A. S. (2021) · Türk Mikrobiyoloji Cemiyeti Dergisi · doi:10.5222/tmcd.2021.71602 · Cited by 1
Mediator Subunit Med15 Regulates Cell Morphology and Mating in Candida lusitaniae
Sabra, A., Biteau, N., Dupuy, J., Klopp, C., Noël, T., & Dementhon, K. (2023) · Journal of Fungi · doi:10.3390/jof9030333 · Cited by 1
“auris, a newly emerging pathogen that is highly resistant to antifungals and responsible for nosocomial outbreaks in several countries [16,17].”
BackgroundInduction and analysis of systemic C. albicans infections in mice
Frank, D. M., & Carpino, N. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2021.12.022
Fungal Infections Complicating COVID-19
Hoenigl, M., & Talento, A. F. (2021) · MDPI eBooks · doi:10.3390/books978-3-0365-0555-8
Perspective Chapter: Antifungal Drug Resistance in Candida Species
Turan, D. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106970
Arastehfar, A. A., Daneshnia, F., Cabrera, N., Penalva-Lopez, S., Sarathy, J. P., Zimmerman, M., Shor, E., & Perlin, D. S. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.21.513290
Self-citationPatro, S. K., Panda, N. K., & Sharma, M. (2023) · Springer eBooks · doi:10.1007/978-981-19-5399-6_12
Yusup, C. A., Eris, D. D., & Priwiratama, H. (2023) · WARTA Pusat Penelitian Kelapa Sawit · doi:10.22302/iopri.war.warta.v28i3.113 · Cited by 1
“…sp., dengan konsentrasi 0,8% polifenol sudah menghasilkan penghambatan sebesar 31,04% terhadap Pestalotiopsis sp. Perbedaan tingkat penghambatan ini dipengaruhi baik oleh faktor mode of action (MoA) bahan aktif, maupun dari faktor perbedaan genetik cendawan targetnya (Arastehfar et al., 2020).”
BackgroundCRISPR systems tackling fungal infections
Leitão, M. D. C., Vieira, H. L. D. A., Fernandes, L., Silva-Pereira, I., & Coelho, C. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91808-4.00009-2
Bendel, C. M., & Swanson, E. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-79525-8.00044-5
Design of Marine Cyclodepsipeptide Analogues Targeting Candida albicans Efflux Pump CaCdr1p
Ribeiro, R., Fortes, S., Costa, L., Palmeira, A., Pinto, E., Sousa, E., & Fernandes, C. (2024) · Drugs and Drug Candidates · doi:10.3390/ddc3030031
“The emergence of multidrug-resistant (MDR) strains of fungi and increasing azole-resistant invasive fungal infections (IFIs) to antifungal treatments poses a serious threat to patient outcomes, especially in developing countries where antifungal agents are limited [2].”
BackgroundInfluentialHilmarsdóttir, I., Alcanzo, E. M., van den Ende, B. G., Houbraken, J. A. M. P., & Hagen, F. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.08.607273
Vargas-Junior, V., Guimarães, A. C. R., Caffarena, E. R., & Antunes, D. (2024) · ACS Omega · doi:10.1021/acsomega.4c00158
Wilson, L., Nielsen, K., Villanueva, S. C., O'Brien, T., Hefner, L. A., Slick, P., Petty, L., Dienna, R., Castillo, H. A., & Chavez, A. A. (2025) · Life Sciences in Space Research · doi:10.1016/j.lssr.2025.01.002 · Cited by 1
Groll, A. H., & Walsh, T. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00256-9
Liu, F., Sun, Y., Zhao, R., Zhang, L., & Deng, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.10.659005
Alencar, G. G., dos Santos, C. A. L., Farias, N. S., Silva, J. T. D. C., dos Santos, A. G., Bezerra, J. D. S., Costa, A. R., Filho, A. M., Macêdo, M. J. F., Rocha, J. E., et al. (2025) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2025.101040
Pituła, E., Kouao, D., Sezemský, P., Kylián, O., Šimerová, R., Grochowska, K., Siuzdak, K., Straňák, V., Koba, M., & Smietana, M. J. (2025) · Journal of Lightwave Technology · doi:10.1109/jlt.2025.3644662
“T O ADDRESS global health threats, including persistent environmental pollutants, the emergence of drug-resistant pathogens, and pandemic outbreaks, the need for novel, highly sensitive, and sustainable detection methods has become critical [1], [2], [3], [4], [5], [6], [7], [8], [9], [10].”
Outcomes and Predictors of Fungal Necrotizing Soft Tissue Infections
Collins, C., Butsch, B. L., Choudhary, M., Ingram, C., Srivatsa, S., Quinn, P., Mowery, N., Jalilvand, A., & Wisler, J. (2026) · Surgical Infections · doi:10.1177/10962964251415294
Hinman, K. D., Machan, J. T., & Lefort, C. T. (2026) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiag020 · Cited by 1
Peng, X. W., Zhang, L., Du, M., Yuan, Q., He, H., Xue, X., Liao, W., Ma, Y. N., Pan, W., & Cai, L. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1906168 · Cited by 1
“As widely used antifungal drugs, azoles and flucytosine face troubles in clinical application due to the growing prevalence of cross-resistance (Arastehfar et al., 2020; Bilal et al., 2022).”
Martín‐Loeches, I., & Yu, Y. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2726965
Omar, A. M., Al-Najjar, M. A. A., Mansoor, K., Nadworny, P. L., Abu-Qatouseh, L., Barakat, M., Alalwani, R. M., Alshaer, S., Omer, L., Alzaghari, L. F., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10788328/v1
Candidozyma auris ( Candida auris ) as a harbinger of novel fungal pathogens
Schuh, C., & Gokhale, C. S. (2026) · mSphere · doi:10.1128/msphere.00109-26
Metadata
- Authors
- Arastehfar, A., Lass-Flörl, C., Garcia-Rubio, R., Daneshnia, F., Ilkit, M., Boekhout, T., Gabaldon, T., & Perlin, D. S.
- Affiliations
- Hackensack Meridian Health (US)
- Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria
- Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA
- Westerdijk Fungal Biodiversity Institute (NL)
- Division of Mycology, University of Çukurova, 01330 Adana, Turkey
- Life Sciences Programme, Barcelona, Supercomputing Center (BSC-CNS), Jordi Girona, 08034 Barcelona, Spain
- Corresponding author
- Arastehfar, Amir
- Perlin, David S.
- ORCID
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2020-08-18
- Volume
- 6
- Issue
- 3
- Pages
- 138
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC7557958
- OpenAlex
- W3070435984
- Semantic Scholar
- ffe1b3b580b5ee9de9aca8e5de0b85b315b7691d
- Cited by
- 145
- References
- 246
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 36 · 2023: 28 · 2022: 22 · 2021: 25 · 2020: 7
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UPCommons institutional repository (Universitat Politècnica de Catalunya) (acceptedVersion, cc-by)
- UvA-DARE (University of Amsterdam) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences) (submittedVersion, other-oa)
- KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (submittedVersion, other-oa)
- Funders
- Astellas Pharma
- National Institutes of Health (AI109025)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- antifungal resistance, invasive fungal infections, Candida auris, Candida glabrata, Candida parapsilosis, Candida tropicalis, Aspergillus, multidrug resistance, azole resistance, antifungal tolerance, molecular mechanisms of resistance, non-albicans Candida, phylogenetic placement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.